Consort Medical

Bringing Aesica together with Bespak within the Consort Medical group builds on Bespak’s rich drug delivery device heritage over the last 50 years and Aesica’s decade-long expansion into a leading European pharmaceutical CDMO. Today, Consort Medical is a leading, global, single source drug and delivery device CDMO. Optimising world-class drug delivery device development and manufacture, together with API and finished dose drug formulation and manufacture, within the same group streamlines and accelerates our pharmaceutical customers’ drug route to market. Consort Medical remains at the leading edge of innovation and is committed to investing in patient- and customer-driven innovation with the potential to create new treatments, new markets and new opportunities.

Type
Public
HQ
Hemel Hempstead, GB
Employees
1,973 (est)

Consort Medical Locations

Hemel Hempstead, GB
Cambridge, GB
Northumberland, GB
North Lynn Industrial Estate, GB
Nelson, GB
Wolverton, GB
Tyne and Wear, GB
Queenborough, GB
Monheim am Rhein, DE
Zwickau, DE
Pianezza, IT

Consort Medical Metrics

Consort Medical Summary

Market capitalization

£503 M

Closing share price

£10.3

Consort Medical Financials

FY, 2014FY, 2015FY, 2016

Revenue

£100 M£185 M£277 M

Revenue growth, %

84.8%49.8%

Cost of sales

£177 M£261 M

Gross profit

£8.16 M£16 M

Gross profit Margin, %

4.4%5.8%

Consort Medical Market Value History

Consort Medical News

Consort Medical Company Life

You may also be interested in